The challenges of the third millennium did not leave the issues and results of scientific faith healing untouched. We announce with honest pride that for over five years, the favourable experiences of controlled clinical examinations and medical research in connection with flavonoids convince more and more patients and doctors about the health preservation, disease prevention and recovery enhancement effects of Flavin 7 diet supplement product and the flavonoid product family.
In 2002, „Flavinnal az egészségért” (With Flavin for Health) public utility civil foundation was established, based on the tender of which 55 volunteering doctors – family doctor, specialist doctor, clinical team of doctors – have carried out multi-centre clinical examinations about the clinical changes, disease prevention and health preservation effects, as well as the changes taking place in the course of the diseases experienced during the course of taking Flavin 7 – licensed food product (OÉTI license number: 25/É), and diet supplement. The supplementary treatment could not replace the methods of cure of the custom-made treatment strategy.
The planned number of patients was 500, of which 150 patients (30%) belonged to the group of heart and circulatory diseases, 250 patients (50%) to malevolent tumour diseases, while 100 patients (20%) to the group of other diseases.
Finally, between 1 November 2002 and 30 October 2003, voluntary patients received different doses of Flavin 7 for six months. During the course of this, doctors taking part in the project carried out the controlled clinical examinations.
Examination took place on the basis of selection criteria, in a random manner.
- Heart and circulatory diseases, cardiologic diseases of the central and peripheral vascular system, cardio-sclerosis and angina-pectoris supported by EKG and echo-cardiograph, patients that have undergone cardiac heart-attack, limb aortic stenosis patients, Raynaud-syndrome, cerebral arteriosclerosis, etc.
- Tumour-diseases – in certain cases benign tumours as well. Malevolent tumour patients supported by histological examination – breast cancer, stomach, internal medicine, lung-bronchial, prostate, gynaecological, central nervous system, head – neck tumours, oncohaematological diseases.
In the case of the selection criteria of patients with malignant tumours, metastasis in the lungs exceeding 50 %, metastasis in the liver constituting 50 %, and disk-metastasis in connection with the central nervous system were reasons for exclusion. In case of the simultaneous occurrence of these, as supported by clinical examinations and experience, not more than six months of survival can be expected.
- Other diseases: liver diseases, allergic diseases, menopausal – climacteric statuses, osteoporosis, sclerosis multiplex, chronic inflammations, Alzheimer’s disease, auto-immune diseases, etc.
Volunteering patients signed a statement of compliance. Doctors defined the clinical status upon selection and 6 weeks, 3 and 6 months after the taking of Flavin 7.
During the monitoring of the patients, the patients’ conditions were evaluated following the diagnostic algorhythms and the therapeutic protocols, accepting the hospital clinical final results.
After the completion of the examination, we requested that a comprehensive study (staging examination) be prepared with respect to every patient.
Examination results
60% of the doctors (33 of the 55 individuals) prepared comprehensive studies that can be evaluated and are sufficient to be processed. 10 doctors – even though they received the examination materials – did not return any information, this affected altogether 79 patients. From 12 doctors, incomplete sheets were returned that were unsuitable to be processed. This was the material of 93 patients. Therefore, 172 patients were left out of the evaluation.
The Foundation provided Flavin 7 for altogether 467 patients.
Of this, clinical examinations were carried out in the case of 295 patients (100%).
1. Heart and circulatory diseases: 31 patients 10,5 %
- Tumour diseases: 232 patients (220 malevolent, 12 benign tumour patients)78,2 %
- Group of other illnesses: 32 patients 11,3 %.
1.) The cardio-respiratory clinical status of 68% of the heart and circulatory patients (that is 21 cases) improved significantly. The condition of 8 patients (26%) stagnated, while a decrease of condition was experienced in 2 cases (6%).
The stamina of heart – vascular patients definitely improved, there was less wheezing, the patients’ blood-pressure became balanced.
The condition of 70% of the malevolent tumour patients – with good quality of life – was securely stable, in the case of 89 (40%) patients, we can talk about definite improvement of condition, remission.
In 65 cases (30%) progression could be experienced.
During the clinical examinations, we found that Flavin 7 substantially improves the patients’ quality of life, it decreases or eliminates the side-effects of chemo – radiation therapy, and had hepato-protective (liver-protective) and cardio-toxicity protective effect. The product decreased the pain of bone-metastasis patients, and – following chemo-therapy treatment – their blood results (white blood cell and thrombocyte number) took shorter to come back to normal. We were surprised to experience that it influenced the patients’ mood in a positive way, we experienced definite anti-depressant effects with several of them.
During the period of monitoring, there were 30 cases of death among the patients with malevolent tumours; of this, 12 patients did not meet the patient selection criteria. These patients were monitored at a very advanced stage. In case of those patients who died during the period of monitoring, the doctors and the patients’ relatives related that they lived in a bearable condition, without pain, almost until the last days of their lives.
3.) Other groups of diseases: cirrhosis of the liver, hepatitis, diabetes, chronic catarrh of the lungs, asthma bronchiole, allergic diseases. The liver-protection function of Flavin 7 was unquestionably proven by the fact that the liver-function results of the de-compensated liver cirrhosis patients became normal. In the case of diabetes mellitus, blood sugar level decreased gradually, and a situation of balance occurred. The nitrogen-oxide exhalation of the patient with chronic catarrh of the lungs and bronchitis significantly decreased, a fact that also refers to the decrease of the inflammation of the respiratory tract. It was interesting to monitor the patient with aortic stenosis caused by a serious level of diabetes, who, at the beginning of the monitoring period, was able to walk only 10 metres without pain (dysbasic distance); some 5-6 months later this distance grew to 200-250 metres. This change was accompanied by the significant improvement of the subjective and psychic status.
The majority of the doctors taking part in the examinations advocate that Flavin 7 had a fairly positive effect on their patients, and emphasise the importance of application in prevention.
We would like to say thanks to the Board of Trustees of „Flavinnal az egészségért” Alapítvány (With Flavin for Health Foundation) for making Flavin 7 available for the time of the examination.
We would like to say thanks to those doctors who contributed to the multi-centre clinical examination of Flavin 7 with their conscious work.
Dr. Erdős Sándor
Oncologist specialist head doctor
Director of the clinical examination
